AngioDynamics Director Lorinda Burgess Receives RSU Award (11,887)

What Happened

• Lorinda Burgess, a director of AngioDynamics, received 11,887 restricted stock units (RSUs) on 2026-07-15. The Form 4 reports the acquisition at $0.00 (grant), and the RSUs immediately vested at grant per the filing footnote. This is an award (routine director compensation), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-22 (appears outside the typical 2-business-day filing window for Form 4s).
• Transaction type/code: Award/Grant (A).
• Amount and price: 11,887 RSUs acquired at $0.00 reported.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The RSUs were granted as regular annual director compensation and vested immediately (Footnote F1).
• Timeliness: Filing date is 7 days after the transaction date; investors may note the filing appears late relative to standard Form 4 deadlines.

Context

• RSUs are a form of equity compensation that convert to shares (or represent the right to receive shares). Because these RSUs vested immediately, Burgess effectively received shares/ownership rather than a deferred award. Such grants are common as routine director compensation and do not necessarily signal the director's view on the company's near-term prospects. To estimate the award's market value, multiply 11,887 by ANGO's share price on the vesting date.